<DOC>
	<DOCNO>NCT01161823</DOCNO>
	<brief_summary>After menopause coronary artery disease ( CAD ) risk increase rapidly equivalent risk men age . The rise incidence CAD could subsequent decline endogenous estrogen blood level menopause . Estrogen lead vasodilation vasoprotection increase Nitric Oxide ( NO ) . NO deficiency result endothelial stiffness dysfunction subsequent initiation atherosclerosis . Menopausal status associate increase sympathetic nerve activity lead hypertension , increased heart rate palpitation . Recent study show importance vasoactive substance ( e.g . NO ) physiology hot flash . Thus , hot flash may associate decreased NO production release . Additionally , well know menopause woman experience change sexual function ( decline libido increase dyspareunia ) due decrease estrogen blood level . Recently , new angiostatic parameter - Endostatin ( ENST ) - show involved EC function . There also evidence ENST level increase NO stimulation . Nebivolol , ß-blocker third generation , show release NO significant amount EC . It safe effective reduce blood pressure target level . However , data effect Nebivolol sexual function , clinical symptom ( palpitation , increase heart rate hot flash ) ENST postmenopausal woman . The present study investigates effect NO-releasing ß-blocker compare phytoestrogen therapy consider clinical sign menopause palpitation , hot flash sexual functioning postmenopausal woman . Therefore , use ß-blocker treatment warrant . Further , study try elucidate role NO release postmenopausal symptom may gain new insight pathophysiology hot flash increase sympathetic nerve activity . Thus , trial explore advantage Nebivolol therapy contrast phytoestrogen therapy . Null hypothesis : Climacteric disorder measure MRS-II patient Nebivolol therapy low patient phytoestrogen therapy . Alternative hypothesis : Climacteric disorder patient measure MRS-II Nebivolol therapy low patient phytoestrogen therapy .</brief_summary>
	<brief_title>Influence Nebivolol Postmenopausal Women</brief_title>
	<detailed_description>1 . Background CAD lead cause mortality woman US well Austria develop country . Major risk factor hypertension , diabetes postmenopausal status . After menopause CAD risk increase rapidly equivalent risk men age . In ethnic group , hypertension prevalent among woman men age 59 . Over 75 year 75,2 % female 63,7 % male perform hypertensive vascular status . Menopausal status associate decline endogenous estrogen level result manifest estrogen deficiency . This estrogen decline also associate subsequent increase risk CAD . The main effect estrogen vasodilatation anti-atherosclerotic action different mechanism . Recent study describe estrogen deficiency subsequently NO deficiency result disorder endothelial function permanent vasoconstriction , one major reason postmenopausal hypertension CAD . Clinical symptom postmenopausal woman : - Palpitations tachycardia Postmenopausal woman complain heart palpitation , throb subjective sense high heart rate tachycardia , explain sympathetic activity postmenopausal woman . This clinical symptom associate significant decrease quality life well- postmenopausal woman . - Hot flash Hot flash common symptom occur postmenopausal woman ( 75 % ) . Hot flash experience feel intense heat sweat rapid heartbeat . The typical duration two thirty minute . Risk factor hot flash - equal CVD - high body mass index smoking . Furthermore , suppose NO decrease postmenopausal woman responsible hot flash . - Sexuality Sexuality important quality-of-life issue , also elderly . Therefore , sexual dysfunction consider serious quality-of-life-related health problem . Furthermore increase dyspareunia decrease libido responsivity correlate decrease estrogen level . - Endostatin ( ENST ) ENST , 20-kDa C-terminal fragment cleave type XVIII collagen , naturally occur protein block formation blood vessel , inhibits EC proliferation , migration angiogenesis . Furthermore , evidence ENST induces acute NO release finally lead vasodilation therefore work endothelial dysfunction . However , since data ENST serum level postmenopausal woman well effect Nebivolol ENST serum level , investigate baseline ENST level 3 month treatment compare patient treat phytohormone . - Nebivolol Nebivolol , ß-blocker third generation , show low blood pressure great safety efficacy men well woman well tolerate . Beneath specific beta-1-receptor blockade Nebivolol NO-releasing effect ß3-receptor-agonism . Nebivolol combines potent ß1-adrenoreceptor-blocking activity ( mostly ascribe D-enantiomer ) additional vasodilating property ( attribute L-enantiomer also D-enantiomer ) . Nebivolol cause vasodilatation vessel reduce progress atherosclerosis main risk factor CVD hypertension . The current general guideline hypertension recommend treatment Thiazide Diuretic first line medication hypertension . In contrary Diuretics ACE-blockers - ß-blockers also reduce heart rate positive antagonistic influence sympathetic nerve system . The augmentation heart rate menopause sense unpleasant unbearable situation postmenopausal woman . Thus , increase sympathetic nerve activity clinical symptom palpitation increase heart rate warrant use ß-blocker treatment cohort . Additionally , hypothesise , improvement endothelial function Nebivolol number hot flash postmenopausal woman reduce . Recent study show positive effect erectile dysfunction men treatment Nebivolol . As physiologic embryologic condition almost similar men woman , expect similar improve effect sexual dysfunction female study group . Therefore , want investigate effect Nebivolol blood pressure , heart rate , hot flash , sexual function , ENST , testosterone level postmenopausal woman menopausal disorder . 1.2 Rationale study We want investigate effect Nebivolol comparison phytoestrogen therapy climacteric disorder measure Menopausal rating scale II ( MRS-II ) . In addition investigate following : - heart rate - number palpitation - number hot flush - sexual function - blood pressure - serum level Endostatin - serum level Testosterone postmenopausal woman . 2 METHODS 2.1 Measurement blood pressure Measurement blood pressure accord Riva Rocci perform begin 12 week ( end study ) . Measurements take sit position five minute rest . Three consecutive measurement take average measurement record . 2.2 ECG A 12-lead ECG write rule AV-block bradycardia ( &lt; 50/min ) . 2.3 Blood parameter Prestudy screening : - FSH - TSH - testosterone - estrogen - DHEA - SHBG - prolactin - BNP - hsCRP - liver parameter - kidney parameter - electrolytes - blood glucose Our patient show blood level estrogen &lt; 20pg/ml FSH &gt; 35 mIU/ml verify status menopause . To rule another endocrine cause possible sexual function alteration check blood level TSH , Prolactin , DHEA ( Dehydroepiandrosterone ) SHBG ( Sex Hormon Binding Globulin ) . 2.4 Analysis Endostatin Within routine blood analysis also detect blood level ENST . The RD191076100 Human Endostatin ELISA sandwich enzyme immunoassay quantitative measurement endostatin protein human serum . 2.5 Female Sexual Function Index We use German version female sexual function index ( FSFI-D ) validate 2004 . This questionnaire proven instrument evaluate female sexual function especially ( post ) menopausal woman . We hand questionnaire twice : At begin study ( 12 week later ) . During completion questionnaire study participant , gynecologist attendant help woman complete questionnaire . This way want analyze treatment Nebivolol effect sexual function woman . We add questionnaire appendix . 2.6 Menopausal Rating Scale II We go use Menopause Rating Scale II ( MRS II ) . This self-assessment scale quantify menopausal symptom include 11 question evaluate `` quality life '' cohort . We hand questionnaire twice : At begin study ( 12 week later ) . During completion questionnaire study participant , gynecologist attendant help woman complete questionnaire . 2.7 Hot flashes/palpitations diary At begin study , diary introduce patient treat physician . There number hot flash palpitation per day write . The diary contains 12 page , one page week . At begin perform anamnesis get inform average number hot flash palpitation per day medication .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>Menopausal patient ( estrogen &lt; 20 pg/ml FSH &gt; 35 mIU/ml ) The patient sexually active The patient hot flush The patient palpitation extrasystole Contraindications betablocker therapy : Patients COPD Patients AVblock Patients bradycardia ( mean heart rate &lt; 50 beat per minute ) Patients hypotension ( RR &lt; 100/80 mmHg ) Patients PAD ( stage III , IV ) Patients Asthma Patients Morbus Raynaud Patients carcinoma Patients , already treat hypertension Patients , receive hormone replacement therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>